PharVision Advisers’s PG&E PCG Stock Holding History

PharVision Advisers’s Portfolio PCG Stock Details PCG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,517	Closed	-$244K	–	761
2025 Q2	$244K	Buy	17,517 +7,487	+75%	+$122K	0.35%	147
2025 Q1	$172K	Buy	+10,030	New	+$166K	0.24%	217

Other funds holding PCG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Third Point New York $4.68B AUM 37.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

PharVision Advisers's PCG Position: Q3 2025 in Review

PharVision Advisers sold out of PG&E (PCG) in Q3 2025, closing a stake of 17,517 shares — an estimated $244K sold.

PharVision Advisers first reported a position in PCG in Q1 2025 and held it in 2 quarters. The position peaked at $244K in Q2 2025. 829 funds tracked by Wall St. Rank hold PCG as of Q3 2025.

PharVision Advisers reported no remaining PG&E position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 17,517 PG&E shares in Q3 2025, an estimated $244K.
PharVision Advisers first reported a position in PG&E in Q1 2025 and held it in 2 quarters.
PharVision Advisers's PG&E position peaked at $244K in Q2 2025.
829 funds tracked by Wall St. Rank held PG&E as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.